Section Arrow
Quote
ATNM.NYSE-M
- Actinium Pharmaceuticals
Quotes are at least 15-min delayed:2025/05/30 22:04 EDT
Last
 1.54
-0.04 (-2.53%)
Day High 
1.565 
Prev. Close
1.58 
1-M High
1.835 
Volume 
75.41K 
Bid
1.51
Ask
1.6
Day Low
1.51 
Open
1.543 
1-M Low
1.345 
Market Cap 
49.29M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.67 
20-SMA 1.57 
50-SMA 1.47 
52-W High 8.64 
52-W Low 1.0292 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-1.47/-1.25
Enterprise Value
50.28M
Balance Sheet
Book Value Per Share
0.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed：2025/05/30 22:04 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.